Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.